We are committed to helping our members with diabetes. Managing this disease is complex. You can assist in simplifying medication regimes by reviewing and eliminating medicines with no added clinical benefit.
The American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) recommend glucagon-like peptide 1 receptor antagonists (GLP-1) as an add-on therapy to oral agents and in combination with insulin for the treatment of diabetes.* Current guidelines by the ADA and AACE, as well as the Food & Drug Administration (FDA), do NOT support combination therapy of GLP-1 and Dipeptidyl peptidase 4 inhibitors (DPP-4) due to lack of added clinical benefit.
*All GLP-1 agonists (except Wegovy and Saxenda) are indicated only for type 2 diabetes.
See the full announcements (EmblemHealth | ConnectiCare) for recommendations for patients on a DPP-4 and GLP-1 and list of medications that have these medicinal components.
JP 62308 06/2023
